N18A Stock Overview
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nemaura Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.69 |
| 52 Week High | US$0.69 |
| 52 Week Low | US$0.61 |
| Beta | 0.34 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -78.03% |
| 5 Year Change | n/a |
| Change since IPO | -91.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| N18A | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | -0.3% |
| 1Y | n/a | -10.1% | 2.8% |
Return vs Industry: Insufficient data to determine how N18A performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how N18A performed against the German Market.
Price Volatility
| N18A volatility | |
|---|---|
| N18A Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: N18A has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine N18A's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 36 | Faz Chowdhury | nemauramedical.com |
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs.
Nemaura Medical Inc. Fundamentals Summary
| N18A fundamental statistics | |
|---|---|
| Market cap | €11.39m |
| Earnings (TTM) | -€11.98m |
| Revenue (TTM) | €71.78k |
158.6x
P/S Ratio-1.0x
P/E RatioIs N18A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N18A income statement (TTM) | |
|---|---|
| Revenue | US$77.04k |
| Cost of Revenue | US$1.55m |
| Gross Profit | -US$1.48m |
| Other Expenses | US$11.38m |
| Earnings | -US$12.86m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | -1,916.30% |
| Net Profit Margin | -16,689.14% |
| Debt/Equity Ratio | -118.8% |
How did N18A perform over the long term?
See historical performance and comparison